President Donald Trump succeeded in convincing Pfizer Inc. to hold off on price increases it had planned for this month.
But the pharmaceutical giant wasn’t the only drug company seeking to charge more for its products in recent days.
In the first 10 days of July, at least ten other drugmakers and biotechnology companies raised prices on at least 20 brand-name medicines, a review of pricing data from Rx Savings Solutions and Bloomberg Intelligence shows.
The increases, for medications for cancer, diabetes, multiple sclerosis, and liver disease, were generally each less than 10 percent. But the price of one little-prescribed ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.